Point72 Asset Management
TPST icon

Point72 Asset Management’s Tempest Therapeutics TPST Stock Holding History

Point72 Asset Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,077
Closed -$2.14M – 1017
2020
Q1 		$2.14M Sell
2,077
-920
-31% -$1.34M 0.02% 495
2019
Q4 		$3.94M Buy
2,997
+2,609
+672% +$3.68M 0.02% 531
2019
Q3 		$538K Hold
388
– – ﹤0.01% 773
2019
Q2 		$875K Hold
388
– – ﹤0.01% 782
2019
Q1 		$1.14M Hold
388
– – 0.01% 794
2018
Q4 		$602K Hold
388
– – ﹤0.01% 860
2018
Q3 		$828K Buy
+388
New +$933K ﹤0.01% 862

Other funds holding TPST

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
B
Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Point72 Asset Management's TPST Position: Q2 2020 in Review

Point72 Asset Management sold out of Tempest Therapeutics (TPST) in Q2 2020, closing a stake of 2,077 shares — an estimated $2.14M sold.

Point72 Asset Management first reported a position in TPST in Q3 2018 and held it in 7 quarters. The position peaked at $3.94M in Q4 2019. 51 funds tracked by Wall St. Rank hold TPST as of Q2 2020.

  • Point72 Asset Management reported no remaining Tempest Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Point72 Asset Management sold 2,077 Tempest Therapeutics shares in Q2 2020, an estimated $2.14M.
  • Point72 Asset Management first reported a position in Tempest Therapeutics in Q3 2018 and held it in 7 quarters.
  • Point72 Asset Management's Tempest Therapeutics position peaked at $3.94M in Q4 2019.
  • 51 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2020.

Based on Point72 Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.